Implementation of a regional multidisciplinary pulmonary embolism response team: PERT-POZ initial 1-year experience.


Journal

Kardiologia polska
ISSN: 1897-4279
Titre abrégé: Kardiol Pol
Pays: Poland
ID NLM: 0376352

Informations de publication

Date de publication:
24 04 2020
Historique:
pubmed: 14 3 2020
medline: 28 4 2021
entrez: 14 3 2020
Statut: ppublish

Résumé

Pulmonary embolism (PE) is the third most common potentially life‑threatening cardiovascular disease. A new approach of pulmonary embolism response teams (PERTs) has been introduced to provide rapid multidisciplinary assessment and treatment of patients with PE. However, detailed data on institutional experience and clinical outcomes from such teams are missing. The aim of this study was to report our experience with the management of PE guided by the PERT-POZ within the first year of operation. We performed a prospective study of PERT-POZ activations at a university care center between October 2018 and October 2019. Patient characteristics, therapies, and clinical outcomes were evaluated. There were 86 unique PERT-POZ activations, and PE was confirmed in 80 patients including: 9 patients (11.25%) classified as low‑risk PE, 19 (23.75%) as intermediate‑low risk, 38 (47.5%) as intermediate‑high, and 14 (17.5%) as high‑risk. Sixty patients (75%) received anticoagulation only, 28 (35%) direct oral anticoagulant, 7 (8.75%) vitamin K antagonist, 23 (28.75%) low-molecular-weight heparin, and 2 (2.50%) unfractionated heparin. Ten patients (12.5%) were treated with catheter‑directed thrombectomy, 6 (7.5%) received systemic thrombolysis, 2 (2.5%) underwent surgical embolectomy, 2 (2.5%) were on extracorporeal membrane oxygenation support, and 2 (2.5%) underwent pharmacomechanical venous thrombectomy. There were 7 (8.75%) in‑hospital deaths, and 2 (2.5%) deaths during a 3‑month follow‑up. Bleeding complications were rare: only 3 patients (3.75%) had major bleeding events, but none after administration of systemic thrombolysis. Our study demonstrated that after the creation of PERT-POZ with a precise activation protocol, patients with intermediate and high‑risk PE received most optimal treatment strategies.

Sections du résumé

BACKGROUND
Pulmonary embolism (PE) is the third most common potentially life‑threatening cardiovascular disease. A new approach of pulmonary embolism response teams (PERTs) has been introduced to provide rapid multidisciplinary assessment and treatment of patients with PE. However, detailed data on institutional experience and clinical outcomes from such teams are missing.
AIMS
The aim of this study was to report our experience with the management of PE guided by the PERT-POZ within the first year of operation.
METHODS
We performed a prospective study of PERT-POZ activations at a university care center between October 2018 and October 2019. Patient characteristics, therapies, and clinical outcomes were evaluated.
RESULTS
There were 86 unique PERT-POZ activations, and PE was confirmed in 80 patients including: 9 patients (11.25%) classified as low‑risk PE, 19 (23.75%) as intermediate‑low risk, 38 (47.5%) as intermediate‑high, and 14 (17.5%) as high‑risk. Sixty patients (75%) received anticoagulation only, 28 (35%) direct oral anticoagulant, 7 (8.75%) vitamin K antagonist, 23 (28.75%) low-molecular-weight heparin, and 2 (2.50%) unfractionated heparin. Ten patients (12.5%) were treated with catheter‑directed thrombectomy, 6 (7.5%) received systemic thrombolysis, 2 (2.5%) underwent surgical embolectomy, 2 (2.5%) were on extracorporeal membrane oxygenation support, and 2 (2.5%) underwent pharmacomechanical venous thrombectomy. There were 7 (8.75%) in‑hospital deaths, and 2 (2.5%) deaths during a 3‑month follow‑up. Bleeding complications were rare: only 3 patients (3.75%) had major bleeding events, but none after administration of systemic thrombolysis.
CONCLUSIONS
Our study demonstrated that after the creation of PERT-POZ with a precise activation protocol, patients with intermediate and high‑risk PE received most optimal treatment strategies.

Identifiants

pubmed: 32165606
doi: 10.33963/KP.15230
doi:

Substances chimiques

Heparin 9005-49-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

300-310

Auteurs

Sylwia Sławek-Szmyt (S)

1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland. sylwia.slawek@skpp.edu.pl

Stanisław Jankiewicz (S)

1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland

Anna Smukowska-Gorynia (A)

1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland

Magdalena Janus (M)

1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland

Aneta Klotzka (A)

1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland

Mateusz Puślecki (M)

Department of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Poznań, Poland; Department of Medical Rescue, Poznan University of Medical Sciences, Poznań, Poland

Marek Jemielity (M)

Department of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Poznań, Poland

Zbigniew Krasiński (Z)

General and Vascular Surgery Institute, Poznan University of Medical Sciences, Poznań, Poland

Bartosz Żabicki (B)

Department of Radiology, Poznan University of Medical Sciences, Poznań, Poland

Waldemar Elikowski (W)

Department of Internal Medicine, Józef Struś Hospital, Poznań, Poland

Marek Grygier (M)

1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland

Tatiana Mularek-Kubzdela (T)

1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland

Maciej Lesiak (M)

1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland

Aleksander Araszkiewicz (A)

1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH